Literature DB >> 21478907

Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk.

G Liu1, S Gramling, D Munoz, D Cheng, A K Azad, M Mirshams, Z Chen, W Xu, H Roberts, F A Shepherd, M S Tsao, D Reisman.   

Abstract

SWI/SNF (SWItch/sucrose non-fermentable) complexes are ATP-dependent chromatin remodeling enzymes critically involved in the regulation of multiple functions, including gene expression, differentiation, development, DNA repair, cell adhesion and cell cycle control. BRM, a key SWI/SNF complex subunit, is silenced in 15-20% of many solid tumors. As BRM-deficient mice develop 10-fold more tumors when exposed to carcinogens, BRM is a strong candidate for a cancer susceptibility gene. In this paper, we show that BRM is regulated by transcription, thus demonstrating that the promoter region is important for BRM expression. We sequenced the BRM promoter region, finding two novel promoter indel polymorphisms, BRM -741 and BRM -1321, that are in linkage disequilibrium (D'≥0.83). The variant insertion alleles of both polymorphisms produce sequence variants that are highly homologous to myocyte enhancer factor-2 (MEF2) transcription factor-binding sites; MEF2 is known to recruit histone deacetylases that silence BRM expression. Each polymorphic BRM insertion variant is found in ~20% of Caucasians, and each correlates strongly with the loss of protein expression of BRM, both in cancer cell lines (P=0.009) and in primary human lung tumor specimens (P=0.015). With such strong functional evidence, we conducted a case-control study of 1199 smokers. We found an increased risk of lung cancer when both BRM homozygous promoter insertion variants were present: adjusted odds ratio of 2.19 (95% confidence interval, 1.40-3.43). Thus, we here demonstrate a strong functional association between these polymorphisms and loss of BRM expression. These polymorphisms thus have the potential to identify a sub-population of smokers at greater lung cancer risk, wherein this risk could be driven by an aberrant SWI/SNF chromatin-remodeling pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21478907      PMCID: PMC3400140          DOI: 10.1038/onc.2011.81

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  51 in total

1.  BAF53 interacts with p53 and functions in p53-mediated p21-gene transcription.

Authors:  Min Wang; Chunsheng Gu; Tianyang Qi; Wen Tang; Ling Wang; Shuyan Wang; Xianlu Zeng
Journal:  J Biochem       Date:  2007-09-18       Impact factor: 3.387

2.  Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.

Authors:  L Girard; S Zöchbauer-Müller; A K Virmani; A F Gazdar; J D Minna
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

3.  Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies.

Authors:  M F Decristofaro; B L Betz; C J Rorie; D N Reisman; W Wang; B E Weissman
Journal:  J Cell Physiol       Date:  2001-01       Impact factor: 6.384

4.  BRG1 mutations found in human cancer cell lines inactivate Rb-mediated cell-cycle arrest.

Authors:  Christopher Bartlett; Tess J Orvis; Gary S Rosson; Bernard E Weissman
Journal:  J Cell Physiol       Date:  2011-08       Impact factor: 6.384

5.  Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer.

Authors:  Junya Fukuoka; Takeshi Fujii; Joanna H Shih; Tatiana Dracheva; Daoud Meerzaman; Audrey Player; Kyeong Hong; Sharon Settnek; Ajay Gupta; Kenneth Buetow; Stephen Hewitt; William D Travis; Jin Jen
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

6.  Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis.

Authors:  David N Reisman; Janiece Sciarrotta; Weidong Wang; William K Funkhouser; Bernard E Weissman
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

7.  BAF60a interacts with p53 to recruit the SWI/SNF complex.

Authors:  Jaehak Oh; Dong H Sohn; Myunggon Ko; Heekyoung Chung; Sung H Jeon; Rho H Seong
Journal:  J Biol Chem       Date:  2008-02-26       Impact factor: 5.157

8.  Discovery of BRM Targeted Therapies: Novel Reactivation of an Anti-cancer Gene.

Authors:  Sarah Gramling; David Reisman
Journal:  Lett Drug Des Discov       Date:  2011-01-01       Impact factor: 1.150

9.  The activity of p53 is differentially regulated by Brm- and Brg1-containing SWI/SNF chromatin remodeling complexes.

Authors:  Yang Xu; Jin Zhang; Xinbin Chen
Journal:  J Biol Chem       Date:  2007-10-15       Impact factor: 5.157

10.  Nuclear run-on assay using biotin labeling, magnetic bead capture and analysis by fluorescence-based RT-PCR.

Authors:  G Patrone; F Puppo; R Cusano; M Scaranari; I Ceccherini; A Puliti; R Ravazzolo
Journal:  Biotechniques       Date:  2000-11       Impact factor: 1.993

View more
  32 in total

1.  Heterozygous missense mutations in SMARCA2 cause Nicolaides-Baraitser syndrome.

Authors:  Jeroen K J Van Houdt; Beata Anna Nowakowska; Sérgio B Sousa; Barbera D C van Schaik; Eve Seuntjens; Nelson Avonce; Alejandro Sifrim; Omar A Abdul-Rahman; Marie-José H van den Boogaard; Armand Bottani; Marco Castori; Valérie Cormier-Daire; Matthew A Deardorff; Isabel Filges; Alan Fryer; Jean-Pierre Fryns; Simone Gana; Livia Garavelli; Gabriele Gillessen-Kaesbach; Bryan D Hall; Denise Horn; Danny Huylebroeck; Jakub Klapecki; Malgorzata Krajewska-Walasek; Alma Kuechler; Matthew A Lines; Saskia Maas; Kay D Macdermot; Shane McKee; Alex Magee; Stella A de Man; Yves Moreau; Fanny Morice-Picard; Ewa Obersztyn; Jacek Pilch; Elizabeth Rosser; Nora Shannon; Irene Stolte-Dijkstra; Patrick Van Dijck; Catheline Vilain; Annick Vogels; Emma Wakeling; Dagmar Wieczorek; Louise Wilson; Orsetta Zuffardi; Antoine H C van Kampen; Koenraad Devriendt; Raoul Hennekam; Joris Robert Vermeesch
Journal:  Nat Genet       Date:  2012-02-26       Impact factor: 38.330

2.  Expression of the mouse MHC class Ib H2-T11 gene product, a paralog of H2-T23 (Qa-1) with shared peptide-binding specificity.

Authors:  Lili Chen; Eduardo Reyes-Vargas; Hu Dai; Hernando Escobar; Brant Rudd; Jared Fairbanks; Alexander Ho; Mathew F Cusick; Attila Kumánovics; Julio Delgado; Xiao He; Peter E Jensen
Journal:  J Immunol       Date:  2014-06-23       Impact factor: 5.422

3.  Modulation of Brahma expression by the mitogen-activated protein kinase/extracellular signal regulated kinase pathway is associated with changes in melanoma proliferation.

Authors:  Aanchal Mehrotra; Srinivas Vinod Saladi; Archit R Trivedi; Shweta Aras; Huiling Qi; Ashika Jayanthy; Vijayasaradhi Setaluri; Ivana L de la Serna
Journal:  Arch Biochem Biophys       Date:  2014-07-12       Impact factor: 4.013

4.  BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.

Authors:  Geoffrey Liu; Sinead Cuffe; Shermi Liang; Abul Kalam Azad; Lu Cheng; Yonathan Brhane; Xin Qiu; David W Cescon; Jeffrey Bruce; Zhuo Chen; Dangxiao Cheng; Devalben Patel; Brandon C Tse; Scott A Laurie; Glenwood Goss; Natasha B Leighl; Rayjean Hung; Penelope A Bradbury; Lesley Seymour; Frances A Shepherd; Ming Sound Tsao; Bingshu E Chen; Wei Xu; David N Reisman
Journal:  Clin Cancer Res       Date:  2016-11-08       Impact factor: 12.531

5.  Genome-wide association study of INDELs identified four novel susceptibility loci associated with lung cancer risk.

Authors:  Juncheng Dai; Mingtao Huang; Christopher I Amos; Rayjean J Hung; Adonina Tardon; Angeline Andrew; Chu Chen; David C Christiani; Demetrius Albanes; Gadi Rennert; Jingyi Fan; Gary Goodman; Geoffrey Liu; John K Field; Kjell Grankvist; Lambertus A Kiemeney; Loic Le Marchand; Matthew B Schabath; Mattias Johansson; Melinda C Aldrich; Mikael Johansson; Neil Caporaso; Philip Lazarus; Stephan Lam; Stig E Bojesen; Susanne Arnold; Maria Teresa Landi; Angela Risch; H-Erich Wichmann; Heike Bickeboller; Paul Brennan; Sanjay Shete; Olle Melander; Hans Brunnstrom; Shan Zienolddiny; Penella Woll; Victoria Stevens; Zhibin Hu; Hongbing Shen
Journal:  Int J Cancer       Date:  2019-10-31       Impact factor: 7.396

6.  SWI/SNF gene variants and glioma risk and outcome.

Authors:  Ernest K Amankwah; Reid C Thompson; L Burton Nabors; Jeffrey J Olson; James E Browning; Melissa H Madden; Kathleen M Egan
Journal:  Cancer Epidemiol       Date:  2012-12-29       Impact factor: 2.984

7.  CARMA: CARM1 methylation of SWI/SNF in breast cancer.

Authors:  Xiaofeng Wang; Charles W M Roberts
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743

Review 8.  Transcriptional regulation and its misregulation in disease.

Authors:  Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-03-14       Impact factor: 41.582

9.  Oncogenic targeting of BRM drives malignancy through C/EBPβ-dependent induction of α5 integrin.

Authors:  L Damiano; K M Stewart; N Cohet; J K Mouw; J N Lakins; J Debnath; D Reisman; J A Nickerson; A N Imbalzano; V M Weaver
Journal:  Oncogene       Date:  2013-06-17       Impact factor: 9.867

10.  Flavonoids from each of the six structural groups reactivate BRM, a possible cofactor for the anticancer effects of flavonoids.

Authors:  Bhaskar Kahali; Stefanie B Marquez; Kenneth W Thompson; Jinlong Yu; Sarah J B Gramling; Li Lu; Aaron Aponick; David Reisman
Journal:  Carcinogenesis       Date:  2014-05-29       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.